Cytokinetics (CYTK) Stock Statistics & Valuation Metrics

Cytokinetics has a market cap or net worth of $4.45B. The enterprise value is $5.27B.

Cytokinetics has 119,187,690 shares outstanding. The number of shares has decreased by -2.65% in one year.

Cytokinetics’s return on equity (ROE) is 4.35 and return on invested capital (ROIC) is -42.18%.

The current PE Ratio of Cytokinetics is -8.94. Cytokinetics’s PEG ratio is 2.56.

In the last 12 months, Cytokinetics had revenue of 18.47M and earned -589.53M in profits. Earnings per share was -5.26.

In the last 12 months, operating cash flow was -395.89M and capital expenditures -3.91M, giving a free cash flow of -399.80M billion.

Cytokinetics pays an annual dividend of ―, resulting in a dividend yield of ―

Cytokinetics upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.

Cytokinetics as a current ratio of 6.17, with Debt / Equity ratio of -582.60%

In the past 12 months, Cytokinetics has paid 0.00 in taxes.

Cytokinetics EV to EBITDA ratio is -11.89, with an EV/FCF ratio of -14.68.

Cytokinetics has $1.08B in cash and marketable securities with $724.00K in debt, giving a net cash position of -$287.34M billion.

Gross margin is -890.46%, with operating margin of -2902.72%, and net profit margin of -3191.11%.

The average price target for Cytokinetics is $77.41, which is 11.43% higher than the current price. The consensus rating is Strong Buy